Is the price fair?
What ARQT's price assumes
Arcutis Biotherapeutics, Inc. trades at 116× earnings against 31.5× for the median Biotechnology name, more expensive than its own group.
116
Trailing P/E · Biotechnology median 31.5 · 3.68× the median: the market pays up for this one
- Price / sales
- 0.01
Price / sales · as of 2026-Q1
- Free cash flow yield
- 1.2%
Free cash flow yield · Biotechnology median 2.4%
- Growth the price implies
- +25%
Growth the price implies · What free cash flow would have to do every year for a decade to justify today's price, discounted at 9.0%.
Details›
- Price / book2026-Q1
- 0.02
- EV / EBIT2026-Q1
- 24.2
- EV / sales2026-Q1
- 0.19
- Healthcare median P/E362 names
- 29.9
- Biotechnology median P/E158 names
- 31.5
- Free cash flow, trailing twelve months
- $39M
- Market capitalisation
- $3.34B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.